

OBIGEN PHARMA, Inc.

Corporate Presentation

Ticker Symbol: 7876

Nov. 21, 2025



www.obigenpharma.com

DISCLAIMER

This presentation and the information contained herein are provided for informational purposes only. The forward-looking statements in this presentation — including, but not limited to, business outlook, financial projections, product development plans, and market strategies — are based on information currently available and assumptions made by the company's management.

Actual results may differ materially due to various risks, uncertainties, and unforeseen factors. The company makes no representation or warranty regarding the accuracy or completeness of the information contained herein and undertakes no obligation to update or revise it in light of future events or circumstances.

This presentation does not constitute an offer, solicitation, or recommendation to purchase or sell any securities and shall not form the basis of, or be relied upon in connection with, any contract or commitment. No part of this presentation may be reproduced or distributed to any third party without prior written consent from the company.

Innovation Rooted in Taiwan

- **Taiwan's First Global Market Entrant** : For over three decades, the botulinum toxin market has been dominated by a few international players, with Taiwan notably absent.
- **Proprietary Strain Breakthrough** : OBIGEN's research team found Taiwan's first proprietary strain — OBI-858 — after screening nearly 500 coastal soil samples.
- **Integrated Biotech Pioneer** : Founded in 2020, OBIGEN is Taiwan's first integrated startup to develop its own patented strain, formulation, and advanced process, positioning to enter the global market.

Global Market Rapid Growth

- Rapid Global Market Expansion fueled by aging populations
- North America, Europe, and Asia identified as key growth regions

Botulinum Toxin Market Size 2023 to 2034 (USD Billion)



Source: <https://www.precedenceresearch.com/botulinum-toxin-market>

Botulinum Toxin Market

Trends, by Region, 2024 - 2030



46.9%

North America Market
Revenue Share, 2023

Source:
www.grandviewresearch.com

Diversified Platform for Aesthetic Applications



Diversified Therapeutic Indications

- **Neurological Disorders**

- ✓ chronic migraine
- ✓ cervical dystonia
- ✓ spasticity (post-stroke upper/lower limb)
- ✓ hemifacial spasm

- **Urological Disorders**


- ✓ overactive bladder (OAB)

- **Glandular Disorders**

- ✓ hyperhidrosis (excessive sweating)
- ✓ sialorrhea (excessive salivation)

- **Ophthalmological**

- ✓ strabismus (crossed eyes)
- ✓ blepharospasm (eyelid spasm)



Medical Efficacy of Botulinum Toxin Treatments*

a. Before injection and injection



a. Before injection



b. One month after injection




b. One month after injection




Spasticity


A Pre-injection



B Post-injection




C Pre-injection



D Post-injection



Cervical Dystonia



Myectomy/Ptosis Repair
for Blepharospasm



Deepak Ramesh, MD
Oculofacial Plastic Surgery

Blepharospasm

Source:

- (1) January 2019 Annals of Indian Academy of Neurology 23(3)
- (2) Front. Neurol., 26 July 2022 Sec. Movement Disorders Volume 13 - 2022
- (3) <https://www.centerfacialplastics.com/eyes/blepharospasm-facial-spasm/>

*The above images are to illustrate the medical use of botulinum toxin and do not imply the use of OBI-858.

Technology, Regulation, Market: Three Engines for Value Creation

- **Differentiated Innovation: First-in-Class Strain, Formulation, and Process**
760 kDa complex with fast onset, long duration, and well-balanced safety profile;
Halal-certified to penetrate Islamic markets.
- **Rapid Clinical Trial Progress: Multi-Country Data Driving Global Expansion**
Trials with advantages of short monitoring periods, rapid enrollments; Taiwan Phase III in progress;
U.S. Phase II trials set to begin; Internationally comparable data to enable faster
global registrations and out-licensing.
- **Leading the Long-Acting Frontier: High Valuation Potential**
Long-acting products in a fast-growing market earn premium valuations and drive strong
licensing and M&A activities.

OBI-858 : Features and Advantages

- **Proprietary Strain & Strategic Patent Positioning**

World's first 760 kDa complex; patented in 12 countries with low IP risks, enabling partnerships and global expansion.

- **Differentiated Long-Acting Efficacy**

Fast onset, extended duration, and well-balanced safety profile addressing unmet aesthetic and therapeutic needs.

- **Premium Vegan Formulation with Halal Certification**

Animal-free and alcohol-free formulation certified Halal, unlocking access to Islamic and vegan markets.

Patents in Key Markets to Build a Robust Technology Moat




Halal-Certified to Unlock Global Islamic Markets

Analysis of the characteristics of exclusive excipients




Excipient technology

Reducing the loss of activity during manufacturing by exclusive excipient technology



Recombinant yeast-derived human albumin

Highly pure human origin-free recombinant human albumins



Trehalose

Use pharmaceutical grade Trehalose as stabilizer (superior to competitors, eg. Lactose)



Fast Onset, Long Durability, Well-Tolerated Safety Profile

- Visible results in 3 days.
- 6-month duration: Fewer injections, lower resistance risk
- Precise injection: Reduced diffusion for higher safety
- Safe formulation: No animal, alcohol, or viral impurities
- Unique molecular weight for true product differentiation
- 1:1 dosing compatibility for seamless physician adoption

Brand Name	OBI-858	Botox
Manufacturer	OBIGEN	AbbVie
Molecular Weight	760 kDa	900 kDa
Dose for glabellar lines	20U	20U
Onset	3 days	5-6 days
Median duration	6 M	3–4 M
Nanogram of toxin (per GL dose)	0.12 ng/20U	0.18 ng/20U
Excipients	rHSA, Trehalose	HSA, NaCl
Finishing method	Lyophilized	Vacuum-drying
Storage before reconstitution	2–8°C (25°C study in progress)	2–8°C
Pricing Strategy	Affordable Premium	High

GMP-Compliant Manufacturing with High Barriers

- **High Biosecurity Standards:** To safeguard personnel and ensure product quality, all R&D, manufacturing, and QC operations must be conducted in high-protection environments.
- **Strict Regulatory and Technical Barriers:** Strains and toxins are dually regulated by TFDA/CDC, with potency, purity, and stability standards far exceeding typical biologics.
- **Complex Manufacturing Challenges :** Reliable high-potency toxin production requires highly selective strains. CMO outsourcing is limited. All facilities operated with full containment under PIC/S GMP compliance.
- **Global Supply Chain Strategy:** API facility designed to support global demand; while lyophilized drug-product site ensures stable supply and scalable capacity through strategic expansion.



Control Drug Lab
Taipei Bioinnovation Park




Drug Substance Plant
HsinChu Biomedical Science Park




Drug Product Plant
Tainan Science Park

Key Milestones



Positioning Strategy: Premium Quality at Competitive Pricing



Commercial Model: Dual-Track Licensing and Distribution

	Sales Strategy	Region	Launch Timeline
Domestic Distribution	- Partner with multinational and regional distributors - Target major aesthetic chains, hospitals, and clinics - OBIGEN to obtain marketing approval and supply finished products	TW	2028
Overseas Licensing	- Form alliances with global Pharma companies - Jointly manage clinical trials and registrations - OBIGEN to export finished products	North America, Europe, China	2029 ~ 2031
Overseas Distribution	- Cooperate with regional distributors - Distributors handle local registrations - OBIGEN exports finished products	Japan, ASEAN, Middle East, Latin America	2028 ~ 2029

Powering Growth — Pursuing Health and Beauty in Harmony

- Maximize platform value through integrated supply chain capabilities
- Capture high-growth market premiums via differentiation
- Accelerate licensing expansion by deepening international partnerships

THANK YOU!

OBIGEN PHARMA

Pursuing Health and Beauty in Harmony.

Ticker Symbol: 7876